Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
5
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
PRQR ProQR Therapeutics
- 1.990
- +0.270+15.70%
Close May 2 16:00 ET
- 1.900
- -0.090-4.52%
Post 20:01 ET
209.37MMarket Cap-5.51P/E (TTM)
2.000High1.730Low1.45MVolume1.750Open1.720Pre Close2.78MTurnover2.25%Turnover RatioLossP/E (Static)105.21MShares4.62052wk High2.09P/B128.23MFloat Cap1.07052wk Low--Dividend TTM64.44MShs Float27.600Historical High--Div YieldTTM15.70%Amplitude0.530Historical Low1.919Avg Price1Lot Size
About ProQR Therapeutics Company
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
Company Profile
SymbolPRQR
Company NameProQR Therapeutics
Listing DateSep 18, 2014
Issue Price13.00
Founded2012
CEOMr. Daniel de Boer
MarketNASDAQ
Employees166
Fiscal Year Ends12-31
AddressZernikedreef 9
CityLeiden
ProvinceZuid-Holland
CountryNetherlands (the)
Zip Code2333 CK
Phone31-88-166-70-00
Websitehttp://www.proqr-tx.com
Company Executives
- Name
- Position
- Salary
- Daniel de Boer
- Chief Executive Officer and Executive Director
- 2.44M
- Sheila Sponselee
- Chief People and Operations Officer
- --
- Rene Beukema
- Executive Director, Chief Corporate Development Officer and General Counsel
- 1.31M
- Jurriaan Dekkers
- Chief Financial Officer
- --
- Dr. Gerard Platenburg, PhD
- Chief Scientific Officer and and Executive Director
- --
- Dr. James S. Shannon, M.D.,M.R.C.P.
- Chairman of the Board
- 132.00K
- Theresa M. Heggie
- Independent Director
- 271.00K
- Alison F. Lawton
- Independent Director
- 126.00K
- Bart Filius, M.B.A.
- Independent Director
- 127.00K
- Dr. Martin Maier, PhD
- Independent Director
- --
- Dr. Dinko Valerio, PhD
- Independent Director
- 150.00K
- Dr. Begona Carreno, PhD
- Independent Director
- 84.00K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now